Keyphrases
Type 2 Diabetes Prevention
100%
Dapagliflozin
100%
Type 2 Diabetic Patients
50%
Clinical Trials
16%
Welcome
16%
Type 1 Diabetes Mellitus (T1DM)
16%
Type I Diabetes
16%
Type 2 Diabetes Mellitus (T2DM)
16%
Diabetes
16%
Clinical Application
16%
Armamentarium
16%
Body Mass Index
16%
MEDLINE
16%
Diastolic Blood Pressure
16%
Elderly People
16%
Nephron
16%
Glycemic Control
16%
Hyperglycemia
16%
Adult Patients
16%
Fasting Plasma Glucose
16%
Cotransporter
16%
Renal Function
16%
Urinary Tract Infection
16%
Pediatric Population
16%
Sulfonylurea
16%
Glycated Hemoglobin
16%
Genitourinary Infection
16%
Conference Proceedings
16%
Reversible Change
16%
Glucose Excretion
16%
Sodium-glucose Cotransporter
16%
Glucose Recovery
16%
Recovery Increase
16%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Dapagliflozin
100%
Patient with Type 2 Diabetes
50%
Urinary Tract Infection
33%
Clinical Trial
16%
Diabetes
16%
Insulin Dependent Diabetes Mellitus
16%
Malignant Neoplasm
16%
Body Mass Index
16%
Pediatrics
16%
Diastolic Blood Pressure
16%
Glycemic Control
16%
Kidney Function
16%
Hyperglycemia
16%
Glucosuria
16%
Sulfonylurea
16%
Glycated Hemoglobin
16%
Cotransporter
16%
Sodium Glucose Cotransporter
16%
Nephron
16%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Dapagliflozin
100%
Urinary Tract Infection
33%
Malignant Neoplasm
16%
Clinical Trial
16%
Insulin Dependent Diabetes Mellitus
16%
Hyperglycemia
16%
Sulfonylurea
16%
Glycosylated Hemoglobin
16%
Cotransporter
16%
Sodium Glucose Cotransporter
16%
Glucosuria
16%